Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$13.32 USD
-0.11 (-0.82%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $13.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TEVA 13.32 -0.11(-0.82%)
Will TEVA be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics
Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's
Other News for TEVA
Prepare for Takeoff With Perrigo
The Generic Drugs Antitrust Case
Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors